By clicking on the above links, you will be leaving our website and Amgen does not endorse or accept liability for sites controlled by third parties

home_banner home_mobile_brand

Lead your patients to stronger bones with Prolia®1,2,3,4

Learn More

What is Prolia®?

Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and in men who are at increased risk of fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.1

During the menopause, oestrogen levels decrease, RANKL expression increases, and this subsequently leads to enhanced osteoclast formation, function and survival.5 Osteoporosis can also occur in men due to ageing or a low level of the hormone testosterone.6 Prolia® mimics the action of the naturally occurring protein osteoprotegerin (OPG) that inhibits and regulates RANK Ligand.1,2

In this way, Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures in post menopausal women.1

Read More

During the menopause, oestrogen levels decrease, RANKL expression increases, and this subsequently leads to enhanced osteoclast formation, function and survival. Osteoporosis can also occur in men due to ageing or a low level of the hormone testosterone. Prolia® mimics the action of the naturally occurring protein osteoprotegerin (OPG) that inhibits and regulates RANK Ligand.1,2

In this way, Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures in post menopausal women.1

image 1

Self injection guide

Watch Video
image 2

How to order Prolia

Learn More
image 3

Mode of action

Watch Video

Adverse events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on: +44 (0) 1223 436441

References:

  1. Prolia (denosumab), Summary of Product Characteristics.
  2. Cummings SR et al, N. Eng. J Med 2009;361:756-765.
  3. Holzer G et al, J Bone Miner Res 2009;24(3):468-74.
  4. Poole K et al; J Bone Miner Res 2012; 27 (suppl1):s44 abstract 1122.
  5. Guitty Eghbali-Fatourechi et al..J Clin Invest. 2003; 111(8): 1221 -1230
  6. Herrera et al. World J Orthop. 2012; 3(12): 223-234

You are now leaving prolia.co.uk

Amgen does not endorse or accept liability for sites controlled by third parties